Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia

A legfontosabb adatok

Ki végzi
Peking University People's Hospital
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
180 fő, tervezett
Kezdés
2026. jún. 15.
Várható befejezés
2029. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • G-CSF-Primed Peripheral Blood Stem Cell Graft
  • G-CSF-Primed Bone Marrow Plus Peripheral Blood Stem Cell Graft
A regiszteradat frissítve
2026. szeptember 16.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with severe or very severe aplastic anemia who will have a stem cell transplant from a half-compatible family donor. It compares two sources of donor stem cells.

Életkor
18 to 40 years
Nem
All sexes
A betegség stádiuma
Newly diagnosed or relapsed severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) by the Camitta criteria. Daily activity level (ECOG) of 0 to 2.
Korábbi kezelés
People who had a donor stem cell transplant or an organ transplant before cannot join.
Biomarker vagy leletérték
Bone marrow cellularity <25% plus at least two of: absolute neutrophil count <0.5 × 10^9/L, platelet count <20 × 10^9/L, reticulocyte count <20 × 10^9/L. For vSAA, absolute neutrophil count <0.2 × 10^9/L.

A részvétel fő kizáró okai

  • Blood cancer or myelodysplastic syndrome-related chromosome changes, such as +8 or del(7q)
  • Having a brother or sister with a fully compatible tissue type (HLA) who can donate
  • Active uncontrolled infection, such as fungal infection, tuberculosis or sepsis
  • Severe other illnesses (HCT-CI score ≥4) or uncontrolled autoimmune disease
  • Donor problems, such as donor age <12 years or >65 years, or donor body mass index <18 or >35 kg/m²

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with newly diagnosed or relapsed severe aplastic anemia (SAA) or very severe aplastic anemia (vSAA) according to the Camitta criteria
  • SAA is defined as bone marrow cellularity <25% and at least two of the following peripheral blood criteria: absolute neutrophil count <0.5 × 10\^9/L, platelet count <20 × 10\^9/L, or reticulocyte count <20 × 10\^9/L
  • vSAA is defined as SAA with an absolute neutrophil count <0.2 × 10\^9/L
  • Age 18 to 40 years
  • Availability of a haploidentical related donor
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ function, defined as follows:
  • Cardiac function: left ventricular ejection fraction ≥50% and no severe arrhythmia
  • Hepatic function: total bilirubin ≤2 times the upper limit of normal and alanine aminotransferase/aspartate aminotransferase ≤3 times the upper limit of normal
  • Renal function: creatinine clearance ≥60 mL/min
  • No active infection
  • For women of childbearing potential, a negative pregnancy test is required
  • All patients must agree to use effective contraception during the study period
  • Written informed consent provided by the patient or legal representative

Ki nem vehet részt

  • Prior allogeneic hematopoietic stem cell transplantation or prior organ transplantation
  • Presence of hematologic malignancy or myelodysplastic syndrome-related chromosomal abnormalities, such as +8 or del(7q)
  • Active uncontrolled infection, including unresolved invasive fungal disease, active tuberculosis, sepsis, or other uncontrolled infections
  • Severe comorbidities, defined as a Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score ≥4, or uncontrolled autoimmune disease
  • Psychiatric illness that prevents cooperation with study procedures, or any condition considered by the investigator to make the patient unsuitable for study participation
  • Donor-related contraindications, including donor age <12 years or >65 years, donor body mass index <18 or >35 kg/m², contraindications to anesthesia, or contraindications to bone marrow harvest
  • Availability of an HLA-matched sibling donor

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 40 év között vagy?

Helyszínek itt: Kína

  • Peking University People's HospitalBeijing, KínaContact: Zhengli XuRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Severe aplastic anemia is a life-threatening bone marrow failure disorder. Haploidentical hematopoietic stem cell transplantation has become an important curative treatment option for patients who do not have an HLA-matched sibling donor.

A teljes eredeti leírásKevesebb

Traditionally, haploidentical transplantation for severe aplastic anemia uses a graft composed of granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells. However, bone marrow collection is invasive and may increase donor burden. Peripheral blood stem cell collection is simpler and less invasive, but it remains unclear whether using peripheral blood stem cells alone provides similar clinical outcomes without increasing the risk of graft-versus-host disease.

This multicenter, randomized, open-label, non-inferiority trial will compare granulocyte colony-stimulating factor-primed peripheral blood stem cells alone with granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells as graft sources for haploidentical transplantation in patients with severe or very severe aplastic anemia. Participants will be randomly assigned in a 1:1 ratio to either graft source group. The primary outcome is the cumulative incidence of grade II-IV acute graft-versus-host disease within 100 days after transplantation. Secondary outcomes include engraftment, chronic graft-versus-host disease, infections, immune reconstitution, survival, and donor safety.

A vizsgálat 2 csoportja

  • G-CSF-Primed Peripheral Blood Stem Cell GraftA vizsgált kezelés

    Participants assigned to this arm will undergo haploidentical hematopoietic stem cell transplantation using granulocyte colony-stimulating factor-primed peripheral blood stem cells alone as the graft source. Donors will receive granulocyte colony-stimulating factor mobilization, and peripheral blood stem cells will be collected by apheresis. Participants will receive the protocol-specified conditioning regimen and graft-versus-host disease prophylaxis.

  • G-CSF-Primed Bone Marrow Plus Peripheral Blood Stem Cell GraftA vizsgált kezelés

    Participants assigned to this arm will undergo haploidentical hematopoietic stem cell transplantation using granulocyte colony-stimulating factor-primed bone marrow plus peripheral blood stem cells as the graft source. Donors will receive granulocyte colony-stimulating factor mobilization, followed by bone marrow harvest and peripheral blood stem cell collection. Participants will receive the protocol-specified conditioning regimen and graft-versus-host disease prophylaxis.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized Controlled Trial Comparing Different Graft Sources for Haploidentical Transplantation in Aplastic Anemia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07629947: ki vehet részt
A regiszteradat frissítve
2026. szeptember 16.